Exosome Therapy in Colombia — What's Actually in That Vial? A 2026 Patient's Guide to Sourcing, Manufacturing, FDA vs INVIMA Regulatory Reality, Cell-Source Transparency (Umbilical Cord MSC, Placental, Adipose, Bone Marrow, Plant-Derived, Platelet-Derived), and the Bedside Questions That Separate Real Exosomes from Marketing

Introduction: The Most Opaque Product Category in Regenerative Medicine

Read 20 articles on exosome therapy and you will see the same set of statements repeated: exosomes are nano-sized vesicles, they are released by cells, they carry signaling molecules, they reduce inflammation, they promote healing, they are minimally invasive, they have a lower risk of rejection than stem cells. Useful background. Necessary, even.

Almost none of those articles answer the question that actually matters when someone is about to inject one of these into your shoulder, your knee, your scalp, your face, or — increasingly — into your nasal cavity for cognitive or neurological indications: what is actually in that vial?

That is the gap this guide closes. Exosomes are the most opaque product category in regenerative medicine. Two products that both call themselves "exosomes" can differ in source cell type, manufacturing process, particle concentration, particle size distribution, sterility validation, lot-to-lot consistency, regulatory status, and whether what is in the vial is actually exosomes at all or a mixed extracellular vesicle preparation labeled with a more marketable word.

If you want the foundational comparison — what exosomes are at a biological level, how they compare to stem cells and PRP, which is the right tool for which condition — read our companion piece: "Exosomes vs Stem Cells vs PRP: Which Regenerative Treatment Is Right for You?" This article assumes you already understand the foundations and goes straight to the sourcing, manufacturing, and verification work.

It is for U.S. patients evaluating exosome therapy in Medellín or anywhere in Colombia and for patients already booked who want to know whether the product they have been quoted is real or whether it is a marketing label on something less defined.

Why Exosome Sourcing Matters More Than Almost Any Other Regenerative Product

Stem cells, when they are autologous (your own adipose-derived stem cells from a mini-liposuction the same day), are sourced from you. The chain of custody is short and verifiable.

PRP, when it is autologous (your own platelet-rich plasma from a blood draw the same day), is also sourced from you. Again, short, verifiable chain of custody.

Exosomes are different. The exosomes used in clinical practice are almost always allogeneic — derived from donor cells in a manufacturing facility, purified, characterized, packaged, shipped, and stored before they reach the clinic. The chain of custody is long. The opportunities for substitution, mislabeling, contamination, sub-standard manufacturing, or simply marketing a product as something it is not are correspondingly larger.

This is not a theoretical concern. It is the reason the U.S. FDA issued a series of public safety alerts and warning letters between 2019 and 2020 specifically about exosome products being marketed in the United States. We will get to that.

The honest framing: exosome therapy from a properly sourced, GMP-certified, well-characterized, well-documented product is a real and useful clinical tool. Exosome therapy from a vial of unknown origin, unknown manufacturing process, and unknown contents is not exosome therapy at all — it is an injection of an unknown biological preparation. The patient has the responsibility, and the right, to verify which one they are receiving.

The Six Source Cell Types You Might Encounter — and What Each Actually Means

Not every product labeled "exosome" comes from the same source. The biological signaling cargo of an exosome is determined by the cell that produced it. This is the single most important variable in determining what the product will actually do.

1. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) Exosomes

Derived from MSCs cultured from donated, ethically sourced umbilical cord tissue. UC-MSC exosomes have the most extensive published preclinical literature in regenerative medicine, particularly for orthopedic, dermatologic, and immunomodulatory indications. They are typically the highest-cost source category and are the most commonly used in serious regenerative clinics in Colombia for clinical applications.

What to verify: the source tissue is ethically obtained with informed donor consent, the donor screening included infectious disease screening (HIV, HBV, HCV, HTLV, syphilis, etc.), the cells were expanded in a GMP-certified facility, and the final product is characterized for particle concentration and identity markers (CD9, CD63, CD81 tetraspanins, plus MSC-specific markers).

2. Placental MSC Exosomes

Derived from MSCs cultured from donated placental tissue. Similar in clinical positioning to UC-MSC exosomes, with comparable signaling profile and similar verification questions. Some clinical literature.

3. Adipose-Derived Stem Cell (ADSC) Exosomes

Derived from MSCs cultured from adipose tissue. Adipose-derived exosomes have a different signaling cargo emphasis than UC-MSC exosomes — more relevant to certain dermatologic and adipose-related indications, less established for some orthopedic applications. Used clinically but less commonly than UC-MSC for the typical regenerative use cases.

4. Bone Marrow MSC Exosomes

Derived from MSCs cultured from bone marrow. Less common in commercial exosome products but biologically reasonable. Different cargo profile than UC-MSC.

5. Plant-Derived Exosome-Like Vesicles

Derived from plant sources (most commonly ginger, ginseng, grape, citrus, or aloe). Plant-derived exosome-like vesicles are biologically distinct from mammalian exosomes — they are a different category of nanoparticle, with their own emerging clinical literature primarily in topical and gastrointestinal applications. They are dramatically less expensive to produce.

This is where one of the most common product-category confusions happens. A clinic offering "exosome facial treatments" at a price that seems too good to be true is often using plant-derived exosome-like vesicles in a topical preparation, marketed under the broader "exosome" umbrella. Plant-derived vesicles in a topical context can be a reasonable lower-cost cosmetic product. They are not the same product as UC-MSC exosomes injected into a knee joint, and you should know which one you are paying for.

6. Platelet-Derived Exosomes (Platelet Exosomes / "PRP Exosomes")

Derived from human platelets, often as a downstream concentration product of platelet processing. A more recent commercial category with growing literature. Biologically distinct from MSC-derived exosomes — the cargo profile reflects platelet rather than mesenchymal origin.

What Most Patients Are Not Told

Most patients are quoted "exosome therapy" without specification of source. They assume they are getting UC-MSC exosomes (the highest-cost, most-studied category). Sometimes they are. Sometimes they are getting a different source product. Sometimes they are getting a topical plant-derived preparation marketed at injection-product prices. The patient has the right to know, and the documentation should specify.

The Terminology Problem: Exosomes vs. Extracellular Vesicles vs. "Exosome Products"

Here is where the marketing language departs from the cell biology.

In strict scientific terminology:

• Exosomes are a specific subset of extracellular vesicles, 30–150 nm in size, derived from the endosomal pathway of the producing cell, and characterized by specific identity markers (the tetraspanins CD9, CD63, CD81, plus markers reflecting endosomal origin).
• Microvesicles are a different subset of extracellular vesicles, typically 100–1,000 nm, derived from outward budding of the cell membrane, with a different molecular signature.
• Apoptotic bodies are a third subset, larger still, released during programmed cell death.

In commercial product practice, most products marketed as "exosomes" are in fact mixed extracellular vesicle preparations containing some true exosomes plus microvesicles and other particles. This is not necessarily a problem — these mixed preparations have legitimate clinical utility. But it is a problem when a product is marketed and priced as a high-purity exosome preparation when it is actually a mixed extracellular vesicle preparation.

The 2018 MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines from the International Society for Extracellular Vesicles set the standard for what a properly characterized exosome product looks like. A serious manufacturer's documentation will reference MISEV compliance and provide the particle characterization data (size distribution by nanoparticle tracking analysis, identity markers by flow cytometry or western blot, particle concentration). A product without that characterization data is essentially undocumented.

The FDA's 2019 and 2020 Public Safety Alerts on Exosome Products

This is the regulatory background that almost no patient-facing exosome article discusses honestly. We will.

In December 2019, the U.S. FDA issued a public safety notification specifically about exosome products being marketed in the United States. The agency stated that there were no FDA-approved exosome products and that some patients in the U.S. had experienced serious adverse events after receiving exosome products that were not properly manufactured or characterized.

In 2020, the FDA issued additional warning letters to U.S. companies marketing exosome products with claims that, in the agency's view, made them drug products requiring FDA approval. Several companies received cease-and-desist communications. A 2019 cluster of bacterial infections at a U.S. clinic following exosome product administration was specifically referenced.

The FDA's position, restated multiple times since: there are no FDA-approved exosome products in the United States. Any exosome product administered in the U.S. is in a regulatory category that requires either an investigational new drug (IND) application for clinical investigation, or operates outside FDA-sanctioned channels.

What This Means Practically for U.S. Patients

It means the regulatory situation in the U.S. is materially different from the marketing language used by some U.S. clinics offering exosome therapy. It also means that for patients who want exosome therapy, traveling to a jurisdiction where the product is properly regulated and the manufacturing chain is verifiable can be the more compliance-respectful path, not the less.

It does NOT mean that exosome therapy is unsafe per se. It means that the safety of any exosome therapy depends entirely on the quality of the source product and the competence of the administering clinic. The 2019 U.S. infection cluster was caused by an inadequately sterile product — a manufacturing failure — not by exosomes as a category.

How INVIMA Handles Exosomes in Colombia

In Colombia, exosome products fall under the framework of cellular and tissue-based products supervised by INVIMA. The regulatory category is distinct from the U.S. regulatory category, but the substantive safety expectations are similar: cell sources must be ethically obtained with donor screening, manufacturing facilities must operate to GMP standards, products must be characterized for identity and concentration, sterility must be validated lot-by-lot, and clinical use must be supervised by a licensed physician with appropriate documentation.

For the regulatory framework background — INVIMA's role, FDA section 503A, magistral preparation — see our companion piece on "Peptide Therapy in Colombia: INVIMA Standards, Safety & Regulations Every US Medical Tourist Should Know (2026)." The same framework principles apply to exosome products with category-specific differences.

For the on-the-ground patient verification work — how to look up physician credentials in RETHUS, how to verify clinic Habilitación through REPS, how to file an adverse event report through INVIMA's FOREAM — see "Verifying Your Medellín Peptide Clinic on Day 1: The On-the-Ground Patient Protection Checklist (2026)."

What GMP-Certified Exosome Manufacturing Looks Like

A real GMP-certified exosome manufacturing operation has:

• A sterile, classified clean-room environment (typically ISO Class 5 or better at the critical processing steps).
• Documented donor screening for the source cells, including infectious disease testing.
• Cell expansion under GMP conditions with documented passage history (lower passage = better; clinical-grade products typically use cells at passage 4 or below).
• A defined exosome isolation method (ultracentrifugation, tangential flow filtration, size-exclusion chromatography, or a validated combination), with the method documented for each lot.
• Lot-by-lot quality control including: nanoparticle tracking analysis for size distribution and concentration, identity marker confirmation (CD9, CD63, CD81, plus source-cell-specific markers), endotoxin testing, sterility testing (USP <71> or equivalent), mycoplasma testing.
• A certificate of analysis (CoA) for each lot specifying all of the above.
• Cold-chain documentation from manufacturing through delivery.
• Stability data for the formulation and storage conditions.

A serious clinic in Medellín can produce the certificate of analysis for the lot of exosome product being administered to you, on request. If they cannot, you have your answer.

The Eight Bedside Questions to Ask Before Any Exosome Administration

These are the questions that distinguish a real exosome protocol from a marketing label. None of them are rude. The serious clinics will answer all of them in five minutes.

1. What is the source cell type?

Acceptable answers identify a specific source category (UC-MSC, placental MSC, ADSC, bone marrow MSC, plant-derived, platelet-derived). "Just exosomes" is not an answer.

2. Who is the manufacturer? Where is the manufacturing facility?

Acceptable answers name the specific manufacturer and city/country. The clinic should be able to tell you whether the product was manufactured in Colombia, the U.S., Europe, or elsewhere, and at which facility.

3. Is the manufacturer GMP-certified? Can I see documentation of the GMP certification?

Acceptable answers confirm GMP certification with available documentation.

4. Can I see the certificate of analysis (CoA) for the specific lot being administered to me today?

This is the most important question. The CoA should specify particle concentration, particle size distribution, identity markers, endotoxin level, sterility validation, and the lot number. A clinic that does not have a CoA for the lot is administering an undocumented biological product.

5. What is the particle concentration in the dose I am receiving?

A meaningful exosome dose is typically expressed in particle count (e.g., 5 billion particles, 10 billion particles, etc.). A clinic that cannot specify the particle count of the dose is administering a product they have not characterized.

6. Has the source cell been screened for infectious diseases? Can I see the donor screening documentation?

For allogeneic products, donor screening for HIV, HBV, HCV, HTLV, and syphilis at minimum should be documented. For some sources, additional screening (CMV, EBV) is appropriate.

7. What is the cold-chain documentation? Has the product been stored under validated conditions from manufacturing through today's administration?

Exosome products typically require frozen storage and cold-chain handling. A break in cold chain can degrade the product.

8. What is the protocol if I have a reaction to this administration?

Same as for any biological administration. The clinic should have a clear answer and the emergency medications and qualified responder available.

Intranasal Exosome Delivery for Cognitive and Neurological Applications

Intranasal exosome administration is a delivery route that has received increasing clinical attention, particularly for cognitive and neurological indications (post-concussion syndrome, post-stroke recovery, mild cognitive impairment, certain neurodegenerative conditions). The biological rationale is that intranasally delivered nanoparticles can bypass the blood-brain barrier through olfactory and trigeminal pathways and deliver signaling cargo to the central nervous system at concentrations that systemic administration cannot achieve.

Where the Evidence Is Today

Intranasal exosome therapy for neurological indications is at an early clinical translation stage. There is preclinical literature. There is early human clinical experience in research and clinical settings. There is not yet a robust randomized controlled trial evidence base supporting routine clinical use for most specific neurological indications.

What That Means for the Patient

It means intranasal exosome therapy can be a reasonable component of a regenerative protocol for the right patient with the right indication, in the right hands, with realistic expectation framing. It is not a "cure" for Alzheimer's disease, post-stroke deficit, traumatic brain injury, or any other neurological condition. Clinics that market it as such are operating ahead of the evidence.

The honest framing: for a patient with post-concussion symptoms or mild cognitive complaints, intranasal exosome therapy as part of a multi-modality regenerative protocol may produce meaningful symptomatic and functional improvement. The honest framing also includes that the response is variable, the durability is uncertain, and the indication is not a primary indication that justifies travel for that alone.

Cross-Reference

For the broader question of when neurological regenerative therapy is and is not appropriate, and what the realistic clinical expectations look like, see our existing companion guides on stem cell therapy for neurological conditions in the cluster.

When Exosomes Alone Underperform

Exosomes are useful. They are also frequently positioned as a stand-alone primary therapy in marketing contexts where the honest clinical reality is that they perform best as a supportive component of a multi-modality protocol.

Where exosomes alone tend to underperform:

• Bone-on-bone end-stage osteoarthritis — exosomes alone do not reverse Grade IV radiographic disease. Stem cells alone do not either. Combined protocols can produce meaningful symptomatic and functional improvement; arthroplasty remains the appropriate intervention for true end-stage OA in the right patient.
• Significant tendon or ligament tears — exosomes alone are inadequate for substantial structural defects. Combined protocols (stem cells + exosomes + PRP, with appropriate sequencing — see our combined therapy sequencing guide) outperform exosomes alone.
• Post-stroke deficit beyond the early window — exosomes alone do not undo established cortical or subcortical infarction. They may contribute to neuroplastic recovery as part of a broader rehabilitation and regenerative protocol.
• Hair restoration on a fully bald scalp — exosomes alone do not regrow hair on follicles that no longer exist. They are a useful component of a hair restoration protocol on scalps where viable but miniaturizing follicles remain (see our combined hair restoration discussion).

Where exosomes shine:

• As a post-procedure recovery accelerator — paired with microneedling, RF microneedling, fractional laser, biostimulators, or post-aesthetic surgery healing. See our GHK-Cu post-procedure recovery guide for the specific stacking with copper peptides.
• As a stem cell signaling amplifier — added to a stem cell protocol to amplify the paracrine signaling cascade (see the combined therapy sequencing guide for the timing).
• As a scalp microinjection adjunct for hair restoration on viable miniaturizing follicles.
• As a dermal rejuvenation tool for skin remodeling on patients with realistic expectations.
• As a post-microneedling recovery accelerator with documented faster epidermal recovery and reduced post-inflammatory hyperpigmentation risk in skin of color.

The honest clinical framing: exosomes are an excellent supportive and amplifying tool. They are not a stand-alone replacement for stem cells in indications where structural cellular contribution is the therapeutic mechanism.

Indication-by-Indication Realistic Evidence Honesty

A short, honest summary of where the clinical evidence stands as of 2026 for the most commonly marketed exosome indications:

• Orthopedic (joint, tendon, ligament): Reasonable evidence as a component of combined protocols. Limited evidence as stand-alone primary therapy for significant structural pathology.
• Dermatology and aesthetics (skin remodeling, post-procedure recovery): Reasonable evidence as a component of post-procedure protocols. Plant-derived topical preparations have a different evidence base than MSC-derived injectable preparations, and the two should not be confused.
• Hair restoration: Reasonable evidence as scalp microinjection adjunct on viable follicles. No evidence for regrowth on truly bald scalps.
• Neurological (post-stroke, post-concussion, cognitive): Early clinical translation stage. Reasonable as a component of a multi-modality regenerative protocol with realistic expectation framing. Not a "cure" for any specific neurological condition.
• Sexual wellness: Limited published evidence; some clinical experience.
• Anti-aging / longevity: Reasonable as a component of a longevity-focused multi-modality protocol; not validated as a stand-alone "longevity drug."

Red Flags That Signal a Clinic Does Not Understand or Will Not Disclose Their Exosome Sourcing

Any one of these is enough to warrant pause.

• Cannot specify the source cell type of their exosome product.
• Cannot name the manufacturer.
• Will not produce a certificate of analysis (CoA) for the lot.
• Cannot specify the particle concentration of the dose.
• Cannot produce donor screening documentation for allogeneic products.
• Cannot demonstrate cold-chain compliance.
• Markets exosome therapy as "FDA-approved" in the United States. (No exosome product is FDA-approved.)
• Markets a topical plant-derived exosome-like preparation at injection-product pricing without disclosing the source.
• Promises results that defy known biology (regrowth on a fully bald scalp, reversal of established cortical infarction, reversal of true end-stage Grade IV osteoarthritis without surgery).
• Aggressively markets unapproved indications (cancer "cure," dementia "reversal," autism "cure," etc.).
• Does not screen for contraindications (active malignancy, active untreated infection, pregnancy, severe organ dysfunction, certain immunosuppressive states).
• Reuses single-use products.
• Stores exosome products at room temperature when frozen storage is required.

Who Is and Is NOT a Candidate for Exosome Therapy

Good candidates

• Post-procedure recovery (after microneedling, fractional laser, biostimulators, aesthetic surgery, hair transplant).
• Component of a combined regenerative protocol with stem cells and/or PRP for orthopedic indications with imaging-confirmed pathology amenable to regenerative protocol.
• Scalp microinjection adjunct for hair restoration on viable miniaturizing follicles.
• Dermal rejuvenation in patients with realistic expectations.
• Component of a longevity-focused multi-modality regenerative protocol.

Not candidates

• Active malignancy or recent malignancy outside case-by-case clearance.
• Active untreated infection.
• Pregnancy and breastfeeding.
• Severe organ dysfunction precluding the procedure.
• Patients on active immunosuppressant or biologic therapy that cannot safely be coordinated.
• Patients seeking guarantees that defy the biology.
• Patients seeking a single-modality replacement for stem cells in an indication where the cellular contribution is the therapeutic mechanism.

Frequently Asked Questions

1. Are exosomes safer than stem cells?

The two have different safety profiles. Allogeneic exosomes have lower theoretical immunogenicity than allogeneic whole stem cells because they do not contain cellular DNA. Autologous stem cells (your own adipose-derived stem cells from a same-day mini-liposuction) have a different safety profile from allogeneic stem cells. The blanket claim that "exosomes are safer than stem cells" oversimplifies the comparison.

2. Are the exosomes used in Medellín the same as the exosomes available at U.S. clinics?

Possibly. Possibly not. The product depends on the manufacturer. Several major exosome manufacturers serve clinics in multiple countries. The right answer is to ask which specific manufacturer your clinic uses and verify their documentation.

3. How do I know the exosome product I receive is sterile?

The certificate of analysis (CoA) for the lot includes sterility validation. Ask for the CoA before administration.

4. Can I bring my own exosome product from a U.S. source?

Discuss with your clinic in advance. Some clinics will incorporate patient-supplied product if the source can be verified. Bring the CoA. Some clinics decline to administer patient-supplied product for liability reasons; that is a reasonable position.

5. How many exosome treatments do I need?

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

6. How long do results last?

Highly indication-dependent. Post-procedure recovery role: the benefit is the accelerated healing of that specific procedure. Stem-cell-amplifier role: the benefit is the amplified durability of the stem cell intervention (months to years for orthopedic and longevity indications). Hair restoration role: typically requires periodic maintenance microinjection.

7. What does an exosome treatment cost in Medellín?

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

8. Can I do exosome therapy if I am on TRT, GLP-1, or HRT?

Generally yes, with coordination with your prescribing physician. None of these are absolute contraindications.

9. What if I want to do exosome therapy alone (not as part of a combined protocol)?

Possible for some indications (post-procedure recovery, dermal rejuvenation, scalp microinjection on viable follicles). For the structural orthopedic and systemic regenerative indications, a combined protocol typically outperforms exosomes alone (see the combined therapy sequencing guide).

10. Is intranasal exosome therapy worth pursuing for cognitive symptoms?

Case-by-case. For a patient with mild cognitive complaints or post-concussion symptoms, intranasal exosome therapy as part of a multi-modality protocol with realistic expectation framing may produce meaningful improvement. It is not a single-modality cure for any specific neurological condition. Have an honest discussion with your prescribing physician about expectations.

Cross-Linked Companion Guides

• Exosomes vs Stem Cells vs PRP: Which Regenerative Treatment Is Right for You? — the foundational comparison.
• Combined Peptide + Stem Cell Therapy in Medellín: The Clinical Sequencing Guide (2026) — for sequencing exosomes within a combined protocol.
• GHK-Cu as a Post-Procedure Recovery Accelerator in Medellín (2026) — for the GHK-Cu + exosomes + PRP three-way regenerative stack.
• Verifying Your Medellín Peptide Clinic on Day 1 (2026) — for the broader credential, sourcing, and adverse event verification framework.
• Peptide Therapy in Colombia: INVIMA Standards, Safety & Regulations (2026) — for the regulatory framework background.
• Peptides vs Stem Cells: Combined Regenerative Therapy at YouMedicine for Americans (2026 Guide) — for the broader combined-therapy context.

Who This Article Is NOT For

• Patients seeking reassurance that "all exosomes are basically the same" — they are not.
• Patients unwilling to ask the eight bedside questions before administration.
• Patients seeking single-modality exosome therapy as a replacement for stem cells in indications where structural cellular contribution is the therapeutic mechanism.
• Patients seeking exosome therapy as a cure for neurological conditions, malignancy, autism, dementia, or other conditions where the evidence does not support those claims.

The Bottom Line

Exosomes are a real, useful regenerative tool. They are also the most opaque product category in regenerative medicine, with the largest gap between what marketing language claims and what the vial actually contains.

Verification protects you. The eight bedside questions take five minutes at a serious clinic and produce immediate clarity at a clinic that does not deserve your business.

The question is not "should I get exosome therapy" — that is an indication-and-context discussion. The question is "do I know what is actually in this vial?" If the answer is yes, the therapy is worth what it costs. If the answer is no, you are not receiving exosome therapy — you are receiving an injection of an undocumented biological product, and no quoted price reflects the value of an undocumented product.

Schedule a Consultation

YouMedicine in El Poblado, Medellín administers exosome therapy as part of integrated regenerative protocols with full source, manufacturer, lot, and characterization documentation. Our exosome product is sourced from a GMP-certified manufacturer, supplied with lot-by-lot certificate of analysis, donor-screening documentation, and cold-chain compliance, and administered with the same documentation standards we apply to every regenerative product.

• Email: wellness@youmedicine.co
• WhatsApp: +57 324 576 1913
• Location: El Poblado, Medellín, Colombia

In your first message, request:

• The source cell type of our exosome product (UC-MSC, ADSC, etc.)
• The manufacturer and manufacturing facility
• A sample certificate of analysis for a recent lot
• The donor screening documentation framework
• The role exosomes play in your specific indication and protocol — stand-alone, post-procedure recovery, stem-cell amplifier, or scalp microinjection adjunct

Every plan is personalized. Message us on WhatsApp and we'll send your quote after reviewing your case.

We will provide everything in advance so you arrive in Medellín already knowing exactly what is in the vial — and the bedside verification work on Day 1 will take five minutes instead of fifty.

YouMedicine — El Poblado, Medellín. Wellness starts with YOU.